Camurus AB
Clinical trials sponsored by Camurus AB, explained in plain language.
Swedish pharmaceutical company developing long-acting drug delivery products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot every 2 weeks could control tumor growth in gut cancers Results expected Nov 2026 (estimated)
-
Can a Once-Monthly shot tame Acromegaly's hormone overdrive?
Disease control CompletedThis trial is testing whether a new, once-monthly injection of octreotide (CAM2029) can help people with acromegaly, a condition where the body makes too much growth hormone. Participants will receive either the study drug or a placebo for six months. The main goal is to see if t…
Phase 3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New monthly injection aims to tame acromegaly safely
Disease control CompletedThis study tested a monthly injection called CAM2029 (octreotide) in 135 adults with acromegaly, a condition where the body makes too much growth hormone. The goal was to see if the drug is safe and keeps hormone levels under control over 12 months. Participants had already been …
Phase 3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC